Article Text

Download PDFPDF
Risk Scale for the diagnosis of antiphospholipid syndrome
  1. Savino Sciascia1,
  2. Domenico Cosseddu2,
  3. Barbara Montaruli2,
  4. Anna Kuzenko1,
  5. Maria Tiziana Bertero1
  1. 1Department of Clinical Immunology, University of Turin, Turin, Italy
  2. 2Laboratorio Analisi, University of Turin, Turin, Italy
  1. Correspondence to Savino Sciascia, Department of Clinical Immunology, AO Mauriziano - Umberto I, Via Ferdinando Magellano 1, 10128, University of Turin, Turin, Italy; savino.sciascia{at}unito.it

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

According to the classification criteria of antiphospholipid syndrome (APS), lupus anticoagulant (LA), anticardiolipin (aCL) and anti-β2-glycoprotein I antibody (aβ2GPI)assays are independent risk factors for the occurrence of vascular thrombosis and pregnancy loss.1 It is generally accepted that patients carrying multiple positivity for antiphospholipid (aPL) antibodies have a more severe disease and higher recurrence rate despite treatment. On the other hand, the stable positivity of a single test is sufficient to classify a patient as having APS.2 As a consequence, clinicians have been wondering whether patients with similar clinical features, but with different positivity patterns (profiles) in the three aPL tests, should be considered completely comparable or not.

We retrospectively studied 3088 consecutive patients who were referred within a 24-month period (January 2007 to January 2009) to coagulation laboratory for the following indications: (A) suspected thrombophilia (thrombotic diathesis), (B) suspected obstetric APS, …

View Full Text

Footnotes

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.